SLC39A1 and pancreatic adenocarcinoma: The results (Figure 2C) demonstrated that SLC39A1 was highly expressed in LIHC patients, SLC39A4 was highly expressed in CESC and PAAD patients, and SLC39A8 was highly expressed in KIRP patients.